We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Set to Acquire Relievant Medsystems
Read MoreHide Full Article
Boston Scientific, Inc. (BSX - Free Report) recently entered into a definitive agreement to acquire the privately held medical device company, Relievant Medsystems, Inc. Together, the teams will explore opportunities to bring Relievant’s Intracept system to a wider population living with chronic low back pain.
The transaction is expected to close in the first half of 2024, subject to the satisfaction of customary closing conditions. The acquisition is intended to expand Boston Scientific’s existing neuromodulation portfolio.
More on the News
The acquisition transaction includes an upfront cash payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three years. Relievant is expected to generate sales of more than $70 million in 2023 and deliver year-over-year growth above 50% in 2024.
Image Source: Zacks Investment Research
On an adjusted basis, the transaction is expected to be immaterial to adjusted earnings per share in 2024, slightly accretive in 2025 and increasingly accretive thereafter. On a GAAP basis, the transaction is expected to be more dilutive due to amortization expenses and acquisition-related charges.
Financial Details
The acquisition transaction includes an upfront cash payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three years. Relievant is expected to generate sales of more than $70 million in 2023 and to deliver year-over-year growth above 50% in 2024.
On an adjusted basis, the transaction is expected to be immaterial to adjusted earnings per share in 2024, slightly accretive in 2025 and increasingly accretive thereafter. On a GAAP basis, the transaction is expected to be more dilutive due to amortization expense and acquisition-related charges.
Industry Prospects
Per a report by Fortune Business Insights, the global chronic lower back pain treatment market was valued at $2.21 billion in 2022 and is expected to witness a CAGR of 9.5% by 2030.
Recent Performance of the Neuromodulation Unit
The company’s Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. In the last reported second quarter of 2023, operational net sales growth was primarily driven by growth within the deep brain stimulation franchise, having witnessed continued momentum from new product launches in the United States and procedure recovery in Europe.
Recently, BSX received FDA approval for the Vercise Neural Navigator 5 software, which, combined with Vercise Genus Deep Brain Stimulation Systems, can help provide clinicians with data for efficient programming in the treatment of Parkinson's disease. Further, Spinal cord stimulation sales growth is expected to improve in the second half of the year, with strong trialing in the second quarter, backed by the company’s recent presentation of clinical evidence at Aspen.
Price Performance
In the past six months, Boston Scientific shares have rallied 10.9% against the industry’s fall of 6%.
Zacks Rank and Key Picks
Boston Scientific currently carries a Zacks Rank #3 (Hold).
Haemonetics stock has risen 22.8% in the past year. Earnings estimates for Haemonetics have increased from $3.74 to $3.82 in 2023 and remained constant at $4.07 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%.
Estimates for Quanterix’s 2023 loss per share have remained constant at 97 cents in the past 30 days. Shares of the company have surged 200.6% in the past year compared with the industry’s rise of 0.3%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for Intuitive Surgical’s 2023 earnings have remained constant at $5.57 per share in the past 30 days. Shares of the company have increased 53.3% in the past year compared with the industry’s growth of 2.8%.
ISRG’s earnings beat estimates in three of the trailing four quarters and missed in one, the average surprise being 4.19%. In the last reported quarter, Intuitive Surgical delivered an earnings surprise of 7.58%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Boston Scientific (BSX) Set to Acquire Relievant Medsystems
Boston Scientific, Inc. (BSX - Free Report) recently entered into a definitive agreement to acquire the privately held medical device company, Relievant Medsystems, Inc. Together, the teams will explore opportunities to bring Relievant’s Intracept system to a wider population living with chronic low back pain.
The transaction is expected to close in the first half of 2024, subject to the satisfaction of customary closing conditions. The acquisition is intended to expand Boston Scientific’s existing neuromodulation portfolio.
More on the News
The acquisition transaction includes an upfront cash payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three years. Relievant is expected to generate sales of more than $70 million in 2023 and deliver year-over-year growth above 50% in 2024.
Image Source: Zacks Investment Research
On an adjusted basis, the transaction is expected to be immaterial to adjusted earnings per share in 2024, slightly accretive in 2025 and increasingly accretive thereafter. On a GAAP basis, the transaction is expected to be more dilutive due to amortization expenses and acquisition-related charges.
Financial Details
The acquisition transaction includes an upfront cash payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three years. Relievant is expected to generate sales of more than $70 million in 2023 and to deliver year-over-year growth above 50% in 2024.
On an adjusted basis, the transaction is expected to be immaterial to adjusted earnings per share in 2024, slightly accretive in 2025 and increasingly accretive thereafter. On a GAAP basis, the transaction is expected to be more dilutive due to amortization expense and acquisition-related charges.
Industry Prospects
Per a report by Fortune Business Insights, the global chronic lower back pain treatment market was valued at $2.21 billion in 2022 and is expected to witness a CAGR of 9.5% by 2030.
Recent Performance of the Neuromodulation Unit
The company’s Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. In the last reported second quarter of 2023, operational net sales growth was primarily driven by growth within the deep brain stimulation franchise, having witnessed continued momentum from new product launches in the United States and procedure recovery in Europe.
Recently, BSX received FDA approval for the Vercise Neural Navigator 5 software, which, combined with Vercise Genus Deep Brain Stimulation Systems, can help provide clinicians with data for efficient programming in the treatment of Parkinson's disease. Further, Spinal cord stimulation sales growth is expected to improve in the second half of the year, with strong trialing in the second quarter, backed by the company’s recent presentation of clinical evidence at Aspen.
Price Performance
In the past six months, Boston Scientific shares have rallied 10.9% against the industry’s fall of 6%.
Zacks Rank and Key Picks
Boston Scientific currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Quanterix (QTRX - Free Report) and Intuitive Surgical (ISRG - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Haemonetics stock has risen 22.8% in the past year. Earnings estimates for Haemonetics have increased from $3.74 to $3.82 in 2023 and remained constant at $4.07 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%.
Estimates for Quanterix’s 2023 loss per share have remained constant at 97 cents in the past 30 days. Shares of the company have surged 200.6% in the past year compared with the industry’s rise of 0.3%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for Intuitive Surgical’s 2023 earnings have remained constant at $5.57 per share in the past 30 days. Shares of the company have increased 53.3% in the past year compared with the industry’s growth of 2.8%.
ISRG’s earnings beat estimates in three of the trailing four quarters and missed in one, the average surprise being 4.19%. In the last reported quarter, Intuitive Surgical delivered an earnings surprise of 7.58%.